Replies to post #500657 on NorthWest Biotherapeutics Inc (NWBO)

[newman2021]

Hi, did u see Kazia failed? Merck failed in their Keytruda combos?? Can you show one such CI combo obtain a patent like DcVaX did? If NICE wouldn't pay an attractive pricing, has it been the whole pharma in UK dead, how are they serving their patients?? Can you tell one naive GBM therapy or rGBM including the device helmet one that works better than the SOCs to date other than DcVaxL?? Do you think FDA would stay quiet hadn't they approved NW's SAP nor SEC continues to allow NWBO to trade without disclosing it??

[Roman516]

HyGro

Your previous posts were based on your opinion, case closed.
The good news is that DCVax-L works, God knows the truth and
all the delays are based on $$$$$$$ offset factors that still favor current
SOC chemo, poison.

Interesting, my search for https://www.nice.org.uk/search?q=process%2Fpmg6
Your search for process/pmg6 returned no results.
However, the link you provided does exist and published in 2012. Perhaps times have changed?

My post on doctor evaluation by multiple doctors is for DCVax-L only, I do not address the FDA or any reference to influencing the FDA.

[biosectinvestor]

DCVax-L is likely to be quite cost effective as the cost covers years of coverage and the lack of side effects does not mushroom other costs. The UK giving DCVax-L the first designation of Promising Innovative Drug, first before drugs coming from the UK.

The doubt they would do that if they did not have strong reason to believe that this will be an innovative drug they hope to have approved by their national insurance program.

You can try to engineer worries, but let’s just focus on the facts. Unlike Car-T, where costs spiral out of control, DCVax-L offers a likely cost effective and symptom light to symptom-less way to treat patients cost effectively over years. Doctors, patients and I believe even insurers are going to like this treatment, which can be given at the doctors office in a quick in and out visit.